PureHealth announced a UK laboratory takeover on 11 September with no terms. The administrators' filing shows a £1,119,499 pre-pack completed on 31 July, sold to the seller's largest customer.
On 11 September 2026 PureHealth announced that its Circle Health Group subsidiary would assume selected UK laboratory operations from Unilabs Limited, with two London hub laboratories and more than 90 external clients. The release disclosed no terms. The UK record fills the gap: Unilabs Limited entered administration on 31 July 2026 and its pathology and blood sciences businesses were sold the same day to Circle Hospital (Reading) Limited for £1,119,499, almost all of it attributed to debtors, with the laboratory equipment transferred at nil attributed value. Circle was the seller's largest customer. It is a supply-continuity rescue, and it is not a valuation comp for UK diagnostics.
What a board member needs before the next meeting on this.
- The deal closed six weeks before it was announced. Unilabs Limited's administrators were appointed on 31 July 2026 and sold the pathology and blood sciences businesses to Circle Hospital (Reading) Limited that day. CQC registered both London laboratory locations to the Circle entity on 31 July 2026. PureHealth's release followed on 11 September.
- The only disclosed price is a distressed price. The administrators' proposals put consideration at £1,119,499: £1,119,496 for debtors and £1 each for stock, other assets and a licence to occupy. PureHealth's own release states no terms.
- The equipment carried book value and no realisable value. Plant and equipment stood at £986,774 of book value at 30 June 2026. The administrators' valuation adviser found most of it between four and 24 years old, largely obsolete, and cheaper to leave than to remove, so it transferred at nil attributed value.
- The buyer was the customer most exposed to the failure. The filing names Circle Health Group as the company's largest customer and a material creditor, dependent on continued service. No open marketing process was run.
On 11 September 2026 PureHealth Holding PJSC announced that its subsidiary Circle Health Group will assume selected UK laboratory operations from Unilabs Limited, naming two hub laboratories in Euston and Cavendish Square, a network of licensed laboratories across the UK, more than 90 external healthcare clients and a Circle network of more than 50 hospitals (PureHealth release, 11 September 2026).
The release discloses no price, no terms and no completion date. Read alone, it looks like a GCC listed group adding a UK diagnostics platform. The seller's side of the record tells a different story, and it is the one a buyer or seller should price from.
The takeover was an administration sale completed on 31 July
Unilabs UK's own site carries a statement that David Pike and Shane Smith of Grant Thornton were appointed joint administrators of Unilabs Limited on 31 July 2026, and that its pathology and blood sciences businesses were sold that day by pre-pack and now trade as PureLab-UK (Unilabs UK statement).
The administrators' proposals, dated 7 August 2026 and filed at Companies House on 28 August, name the purchaser as Circle Hospital (Reading) Limited, company 06995585, and the transaction date as 31 July 2026 (Joint Administrators' proposals, Unilabs Limited 04115820). The Care Quality Commission lists the Stephenson Way and Cavendish Street laboratories under Circle Hospital (Reading) Limited, both registered on 31 July 2026, and archived the Unilabs Limited provider on 4 August 2026 (CQC provider record).
The price is £1,119,499 and it is not a valuation
The same proposals put consideration at £1,119,499, allocated £1,119,496 to debtors and £1 each to stock, other assets and a licence to occupy, with no open marketing process run before the appointment. Gordon Brothers, instructed by the administrators, found the laboratory equipment between four and 24 years old and mostly obsolete, and advised that removing it from basement sites in central London would cost more than it could fetch, so it transferred at nil attributed value against a book value of £986,774 at 30 June 2026.
On our read of the filing's Appendix D, the £1,119,496 matches the amount the administrators expect to realise from a receivable owed by Circle Health, carried at £1,666,757. Anyone quoting £1.12m as the price of a UK diagnostics network is quoting a debtor book.
The buyer was the customer that could not afford the failure
The proposals record that Unilabs Limited was losing approximately £500,000 a month, funded by its parent, Unilabs Laboratoire d'Analyses Médicales SA, which declined to continue. They describe Circle Health Group as the company's largest customer and a material creditor, dependent on continued service and therefore uniquely placed to complete on an accelerated timetable.
The administrators concluded that no credible party existed for the company on a solvent basis. PureHealth presents the deal as extending its PureLab operating model into the UK. The dated sequence shows the order of events: a supplier's funding was withdrawn, and the customer that most needed the laboratories running bought them.
What transferred carries obligations the headline omits
All 57 employees transferred under the Transfer of Undertakings (Protection of Employment) Regulations 2006, according to the proposals; regulation 8(7) removes that effect only where proceedings are instituted with a view to liquidating the transferor's assets (TUPE 2006, regulation 8). The purchaser took a licence to occupy both London premises, alongside a transitional services agreement dated 31 July 2026.
CQC treats a sale and transfer as an incoming provider applying for registration, completed on legal confirmation from both sides (CQC sale and transfer guidance). The filings describe two operating sites; we found no disclosure itemising the wider UK laboratory network the release refers to.
The warning was on the public register in December
Unilabs Limited's accounts for 2024, filed on 29 December 2025, reported turnover of £18,677,112, a loss of £4,098,020 and net liabilities of £3,667,037, against net assets of £430,983 a year earlier, with going concern resting on membership of a group with considerable financial resources (Unilabs Limited accounts, year to 31 December 2024). Seven months later that support was withdrawn, and a laboratory supplier Circle depended on was in administration.
Four questions for a group that depends on outsourced clinical services
- Which clinical suppliers would stop a service line within a week if they failed, and does any single one of them carry more than one site's worth of our volume?
- For each of those suppliers, what do the latest filed accounts show about net assets, and does the going-concern statement rest on support from a parent that has no obligation to continue it?
- If a critical supplier entered administration tomorrow, is our position to buy the business, re-tender the volume, or take the service in-house, and has anyone costed the regulatory registration and staff transfer that each route implies?
- When we read a peer's outbound acquisition announcement as a pricing signal, do we check the counterparty's own registry filings before the number enters a valuation paper?
The Monday work is finite. List the clinical suppliers whose failure would halt a service line inside a week, pull each one's latest registry accounts, and mark every going-concern statement that rests on a parent's goodwill. Decide in advance whether the answer to a failure is to buy, re-tender or insource, and cost the staff transfer and regulatory registration each route carries. Before any outbound deal announcement enters a valuation paper, read the counterparty's own filings. That platform and portfolio work is where our strategic advisory practice begins.
Subscribe
The UAE healthcare regulatory briefing
What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.
One email a fortnight. Unsubscribe from any of them.